Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia

Fig. 5

In vivo evaluation of CX-4945 and DEC. a Longitudinal observation of leukemic blast proliferation in four representative SEM-ffluc xenograft mice is displayed following vehicle (NaCl supplemented with 5% DMSO, BID d7–12), CX-4945 (50 mg/kg body weight (BW), BID d7–12), DEC (0.4 mg/kg BW, d7–10) or CX-4945 plus DEC treatment over a period of 30 days. Increasing luminescence (ph/s) is proportional to proliferation of luciferase-expressing SEM-ffluc cells. b Quantification of full body bioluminescence (ph/s) after treatment in SEM-ffluc and RS4;11-ffluc animals was performed by adding total luminescence signals of dorsal and ventral imaging. Significant differences are indicated for combined treatment of CX-4945 and DEC vs CX-4945 mono application. CX-4945 alone induced no significant change in full body bioluminescence compared to controls (mean + SD; * p < 0.05, ** p < 0.01, *** p < 0.005). Blast frequency in PB was assessed by flow cytometry measurement of GFP+ SEM-ffluc and GFP+ RS4;11-ffluc cells over a period of 30 days. Significant differences are indicated for combined therapy vs CX-4945 mono application (mean + SD; * p < 0.05, *** p < 0.005). Infiltration of leukemic blasts was analyzed in BM and spleen after euthanasia on day 30. The amount of GFP+ SEM-ffluc and RS4;11-ffluc blasts was determined by flow cytometry (mean + SD; * p < 0.05, *** p < 0.005)

Back to article page